Overview
NEOG market data
Price History
NEOG price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.82 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -0.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.90 – $12.85 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.5B · P/B 0.93 · P/S 2.90.
Company News
8-K filing — NEOGEN CORP (NEOG)SEC EDGAR · Aug 7, 2026, 8:02 PM
Piper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13Benzinga · Aug 3, 2026, 4:02 PM
Neogen shares are trading higher after the company reported better-than-expected Q4 financial results.Benzinga · Jul 30, 2026, 5:51 PM
Neogen Sees Q1 Sales $207.000M-$209.000M vs $204.710M EstBenzinga · Jul 30, 2026, 11:03 AM
Neogen Q4 Adj. EPS $0.09 Beats $(0.07) Estimate, Sales $225.300M Beat $212.355M EstimateBenzinga · Jul 30, 2026, 11:02 AM
Neogen Sees FY2027 Sales $880.000M-$885.000M vs $849.644M EstBenzinga · Jul 30, 2026, 11:02 AM
Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in AustraliaBenzinga · Jul 17, 2026, 1:57 PM